Replies to post #12790 on MannKind Corp. (MNKD)

[JLS]

"The idea is not new, the execution and technology are new"

Now we're getting somewhere: "The idea is not new ..."

As far as execution and technology of the inhaler goes, that consists of not only inhaler design (which isn't very imaginative, given all the small inhalers for various things that are already on the market), but also consists of putting into place inventory, production, marketing, sales, and delivery plans so that MannKind could hit the road running as soon as they got approval. To have failed all those parts of a business plan is certainly not a paradigm shift -- rather, it's a classical example for a college freshman class in business school regarding how NOT to run a new product development.

So it boils down to the technosphere being the only possible paradigm shift. But the technosphere, and how it was used, is a single item, an invention at most, but not a paradigm shift. A paradigm is a scientific process consisting of many things in general, such as concepts, research methods, theories, postulates, standards, ..., et cetera.

The number of things that science has allowed people to spray into their lungs is mighty few. The day may come when the FDA will no longer allow technospheres to be sprayed into lungs.

[SidVicious]

Not exactly correct. While some may be able to ditch a needle, not all will. Afrezza won't work for everyone and T1s still need to take a basal insulin which is still injected. It has been suggested that Sanofi would love to become the leader with a Toujeo and Afrezza 1/2 punch. Toujeo is there new one a day injected basal insulin.